Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

134 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Diagnostic challenges of Parkinsonism occurring in multiple sclerosis.
Moccia M, Erro R, Montella S, Carotenuto A, Pappatà S, Orefice G. Moccia M, et al. Among authors: orefice g. Acta Neurol Belg. 2015 Sep;115(3):513-5. doi: 10.1007/s13760-014-0368-x. Epub 2014 Oct 12. Acta Neurol Belg. 2015. PMID: 25308110 No abstract available.
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V. Lanzillo R, et al. Among authors: orefice g. Mult Scler. 2010 Apr;16(4):450-4. doi: 10.1177/1352458509358909. Epub 2010 Feb 11. Mult Scler. 2010. PMID: 20150398 Clinical Trial.
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, Francia A, Florio C, Orefice G, Tedeschi G, Bellantonio P, Annunziata P, Grimaldi LM, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Brescia Morra V; ARIANNA study group. Lanzillo R, et al. Among authors: orefice g. Mult Scler. 2016 Aug;22(9):1163-73. doi: 10.1177/1352458515611222. Epub 2015 Oct 14. Mult Scler. 2016. PMID: 26466947 Clinical Trial.
Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
Lugaresi A, Durastanti V, Gasperini C, Lai M, Pozzilli C, Orefice G, Sotgiu S, Pucci E, Ardito B, Millefiorini E; CoSa Study Group. Lugaresi A, et al. Among authors: orefice g. Clin Neuropharmacol. 2008 May-Jun;31(3):167-72. doi: 10.1097/wnf.0b013e3181571a8e. Clin Neuropharmacol. 2008. PMID: 18520983
Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability.
Tedeschi G, Dinacci D, Lavorgna L, Prinster A, Savettieri G, Quattrone A, Livrea P, Messina C, Reggio A, Servillo G, Bresciamorra V, Orefice G, Paciello M, Brunetti A, Paolillo A, Coniglio G, Bonavita S, Di Costanzo A, Bellacosa A, Valentino P, Quarantelli M, Patti F, Salemi G, Cammarata E, Simone I, Salvatore M, Bonavita V, Alfano B. Tedeschi G, et al. Among authors: orefice g. J Neurol Sci. 2007 Dec 15;263(1-2):15-9. doi: 10.1016/j.jns.2007.07.004. Epub 2007 Aug 1. J Neurol Sci. 2007. PMID: 17673234
Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b.
Lanzillo R, Prinster A, Scarano V, Liuzzi R, Coppola G, Florio C, Salvatore E, Schiavone V, Brunetti A, Muto M, Orefice G, Alfano B, Bonavita V, Brescia Morra V. Lanzillo R, et al. Among authors: orefice g. J Neurol Sci. 2006 Jun 15;245(1-2):141-5. doi: 10.1016/j.jns.2005.08.023. Epub 2006 Apr 19. J Neurol Sci. 2006. PMID: 16626758 Clinical Trial.
134 results